A general and efficient strategy for the synthesis of high-mannose oligosaccharides is described wherein regioselective glycosylations between acetimidate donors and partially protected acceptors are employed to reduce the number of protection-deprotection steps. Two representative branched mannose oligosaccharides, a mannose heptasaccharide (Man 7 ) and a mannose nonasaccharide (Man 9 ) were constructed via (4+3) and (5+4) glycosylations, respectively. These mannose-containing oligosaccharides were obtained in nine steps in ~25% overall yield and >98% purity on 60-70 mg scales to demonstrate the effectiveness of the strategy.
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Introduction
High-mannose N-glycans appended to N-linked glycoproteins play important roles in many normal and aberrant biological processes. 1 For example, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 2 expression are often observed. For example, in the blood sera of breast cancer patients, concentrations of a nona-mannoside (Man 9 ) glycan increase while the sera of normal individuals contain mostly complex-and hybrid-type N-glycans. 4 In another example, mice implanted with head and neck tumors display high concentrations of Man 5 -Man 7 N-glycans in their sera compared to the sera of healthy mice. 5 Access to structurally diverse and chemically pure samples of high-mannose N-glycans is critical for immunological studies and for the development of vaccines.
Several synthetic strategies have been reported to prepare high-mannose oligosaccharides, 6 including tri-to octa-mannosides, but many are situationspecific. Generalized synthetic protocols are still needed. Chemical syntheses of building blocks, including donors and acceptors, often require elaborate design and preparation to allow regio-and stereoselective control of each O-glycosidic linkage formed during assembly. Since there is little theoretical guidance in the design of building blocks, this work is often highly empirical and challenging.
One way to simplify these syntheses is to reduce the number of protectiondeprotection steps by partially protecting the hydroxyl groups in the building blocks, especially in acceptors, and applying them in regioselective glycosylation.
Successful application of lightly protected acceptors exploits intrinsic differences in the regioselectivities and/or relative reactivities of the free hydroxyl groups in the acceptor. Fortunately, significant advances in this understanding have been made over the past few decades.
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In this report, we describe a general and efficient chemical strategy for the rapid assembly of high-mannose oligosaccharides, illustrated with the syntheses of two representative oligomannoses, heptasaccharide 1 and nonasaccharide 2 (Scheme 1). The strategy takes advantage of regioselective glycosylation and the repetitive use of several building blocks with common protecting groups. For example, heptasaccharide 1 was assembled from tetrasaccharide donor 3 and partially protected trisaccharide acceptor 4 through regioselective glycosylation.
Donor 3 was prepared from monosaccharide donor 5 and partially protected acceptor 4. Acceptor 4 was constructed from disaccharide donor 6 and lightly 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   3 protected monosaccharide acceptor 7. In a similar fashion, nonasaccharide 2 was prepared by a straightforward route enabled by the common Man12Man motifs present on the 13 and 16 arms of donor 8. This strategy streamlined the syntheses of 1 and 2 by significantly reducing the number of synthetic steps and improving overall yield. As part of a larger NIHfunded project, >50 branched high mannose oligosaccharides have been prepared in high purity and in 20-100 mg quantities using this general strategy.
Scheme 1.
Structures of target heptasaccharide 1 and nonasaccharide 2 and their retrosynthetic analyses. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   4 The synthetic strategy described above starts with the preparation of basic building blocks. Elementary mannosyl donors, including mannose monosaccharide donor 5, 8 and the -1,2-linked di-and trisaccharide donors 6 and 11, 9,10 were synthesized using methods reported previously. The partially protected triol acceptor 7 was obtained by silylation of allyl -D-mannopyranoside with tert-butyl(chloride)diphenylsilane (TBDPSCl).
Results and Discussion
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Previous investigations of the regioselective mannosylation of a 2,3,4-triol mannoside, 12 showed that the 3-OH exhibits much greater reactivity than 2-OH and 4-OH. Glycosylation of allyl 6-O-TBDPS--D-mannopyranoside (7) with Schmidt's trichloroacetimidate donors in dichloromethane occurred nearly exclusively at the 3-OH position and in good yield with either TMSOTf or BF 3 ·OEt 2 as the catalyst. Subsequent regioselective glycosylations were performed between acceptor 7 with donors 6 and 11 upon activation with TMSOTf at -35 C, easily affording compounds 12 and 13, respectively, in good yields. This strategy simplified the need for protective group manipulations, and avoided the use of other specific catalytics.
13
The newly formed linkages in compounds 12 and 13 were confirmed from analyses of 1D deallylated with palladium chloride (PdCl 2 ), and purified by chromatography on a Bio-Gel P-2 column to give 60-70 mg of oligosaccharides 1 and 2 in >98% purity (Scheme 4).
Scheme 4.
Syntheses of oligosaccharides 1 and 2.
Conclusion
A general and efficient chemical strategy has been developed to prepare tri-antenna mannose oligosaccharides in >20% overall yields. Regioselective glycosylation with partially protected acceptors was employed to reduce the number of protection-deprotection steps, thus improving the overall efficiency of the syntheses. The strategy significantly improves access to these important oligosaccharides on milligram-gram scales, which will promote their use in chemical, biochemical, structural, and biomedical studies.
Experimental Section
General Methods
All chemicals were purchased as anhydrous reagent grade and were used without further purification unless otherwise noted. All reactions were performed under anhydrous conditions. Reactions were monitored by thin-layer chromatography (TLC) on silica gel precoated aluminum plates. Zones were detected by heat/charring with a p-anisaldehyde-sulfuric acid visualization 
Desilylation. The compound was dissolved in anhydrous THF, and
AcOH and TBAF were added to the solution. The solution was stirred at room temperature for 2 h, concentrated in vacuo, and the residue was purified by flash chromatography on a silica gel column.
Acetylation.
The compound was dissolved in anhydrous pyridine, and 4-(dimethylamino)pyridine (DMAP) and Ac 2 O were added to the solution. The solution was stirred for 1 h at room temperature, and concentrated under high vacuum. The residue was partitioned between EtOAc and water, and the organic layer was washed with saturated aqueous NaHCO 3 and brine, dried over anhydrous Na 2 SO 4 , and concentrated in vacuo. The residue was purified by flash chromatography on silica gel column. 4.2.6. Deacetylation. The compound was dissolved in anhydrous methanol and a small amount of NaOMe was added to the solution until the pH reached 9 (pH was determined using pH paper). The reaction solution was stirred at room temperature overnight, and then neutralized with batch addition of Dowex ® HCR W2 ion-exchange resin in the H + form (16-40 mesh) . The resin was removed by filtration, and the filtrate was concentrated in vacuo.
Experimental Data
Allyl 2,3,4,6-tetra-O-acetyl--D-mannopyranosyl-(12)-3,4,6-tri-Oacetyl--D-mannopyranosyl-(13)-6-O-(tert-butyldiphenylsilyl)-α-Dmannopyranoside 12.
Compound 12 was prepared using the general glycosylation method above with donor 6 (6.38 g, 8.17 mmol), acceptor 7 (5.61 g, 12.25 mmol), CH 2 Cl 2 (300 mL), 4Å molecular sieves (7 g), and TMSOTf (300 L, 1.63 mmol). The product was obtained as a white amorphous foam (6.68 g, 6.21 mmol, 76%). 99, 170.95, 170.61, 170.04, 169.93, 169.69, 169.67, 135.79, 135.76, 133.66, 133.08, 132.93, 130.08, 130.05, 127.97, 127.95, 118.08, 100.06, 98.95, 98.72, 79.87, 76.37, 71.60, 70.47, 70.26, 69.87, 69.24, 69.15, 69.01, 68.59, 68.16, 66.89, 66.57, 65.16, 62.83, 62.68, 26.99, 21.06, 20.96, 20.91, 20.88, 20.85, 20.84, 19.33 16, 171.08, 170.13, 169.97, 169.72, 169.60, 133.66, 118.02, 100.36, 99.26, 99.14, 80.33, 77.10, 72.48, 70.97, 70.75, 69.96, 69.36, 69.04, 68.60, 68.33, 66.59, 66.54, 65.78, 62.79, 62.77, 61.32, 21.06, 21.01, 21.00, 20.89, 20.87, 20.85 was prepared using the general glycosylation method above with donor 11 (1.07 g, 1.00 mmol), acceptor 7 (690 mg, 1.51 mmol), 4Å molecular sieves (1.5 g), and 
Allyl 2,3,4,6-tetra-O-acetyl--D-mannopyranosyl-(12)-3,4,6-tri-Oacetyl--D-mannopyranosyl-(12)-3,4,6-tri-O-acetyl--D-mannopyranosyl (13)-α-D-mannopyranoside 9.
Compound 9 was synthesized using the general desilylation method above with compound 13 (1.06 g, 0.78 mmol), THF (50 mL), AcOH (134 L, 2.34 mmol) and TBAF (1.56 mL, 1.56 mmol). The product was obtained as a white amorphous foam (0.87 g, 0.77 mmol, 99%). 93, 170.71, 170.53, 170.49, 170.33, 170.12, 169.94, 169.93, 169.88, 169.83, 169.80, 169.54, 169.50, 133.03, 118.87, 99.87, 99.76, 97.34, 96.18, 78.33, 74.75, 70.93, 69.72, 69.69, 69.66, 69.61, 69.50, 69.48, 69.02, 68.73, 68.64, 68.61, 68.45, 66.81, 66.31, 66.07, 65.68, 62.73, 62.47, 62.22, 21.00, 20.98, 20.97, 20.93, 20.88, 20.86, 20.83 (×2), 20.82, 20.81, 20.77, 20.75, 20.72 
2,3,4,6-tetra-O-acetyl--D-mannopyranosyl-(16)-[2,3,4,6-tetra-Oacetyl--D-mannopyranosyl-(12)-3,4,6-tri-O-acetyl-α-D-mannopyranosyl-(13)]-2,4-di-O-acetyl-α-D-mannopyranosyl trichloroacetimidate 3.
Compound 16 was prepared using the general deallylation method above with 170.70, 170.35, 170.29, 170.24, 170.05, 169.87, 169.83, 169.80, 169.75, 169.67, 169.45, 169.45, 159.51, 99.70, 97.36, 94.13, 90.63, 78.14, 77.02, 73.79, 71.88, 69.78, 69.70, 69.64, 69.49, 69.45, 69.29, 68.97, 68.55, 68.36, 68.08, 66.38, 66.33, 66.01, 65.45, 62.59, 62.31, 61.92, 60.45, 21.13, 20.98, 20.97, 20.95, 20.86, 20.83, 20.78, 20.76, 20.75, 20.74, 20.71, 20.69 4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 (d, J = 1.9 Hz, 1H), 4.24 (dd, J = 9.6, 3.5 Hz, 1H), 3H), 6H), 5H), 3.90 (dd, J = 3.0, 2.1 Hz, 1H), 3.75 (dd, J = 10.9, 5.9 Hz, 1H), 3.56 (dd, J = 10.9, 2. 25, 171.00, 170.95, 170.91, 170.85, 170.82, 170.48, 170.45, 170.40 (×2), 170.11, 169.99, 169.96, 169.94, 169.91, 169.90, 169.60, 169.57, 169.53, 169.50, 133.69, 118.09, 100.79, 99.70, 99.57, 99.28, 99.21, 97.04, 97.02, 81.99, 77.97, 76.98, 74.52, 71.58, 71.04, 70.57, 70.37, 69.89, 69.83, 69.72, 69.62, 69.59, 69.52, 69.28, 69.25, 69.11, 68.80, 68.79, 68.55, 68.49, 68.48, 68.37, 66.84, 66.72, 66.53, 66.40, 66.34, 66.11, 65.83, 65.67, 62.95, 62.65, 62.60, 62.50, 61.89, 21.20 -20 .77. 97, 172.79, 172.66, 172.64 (×2), 172.48, 172.32, 172.30, 172.17, 171.85, 171.84, 171.79, 171.75, 171.68, 171.56, 171.53, 171.47 (×4), 171.45, 171.38, 171.35, 171.29, 171.28, 171.22, 135.33, 118.06, 102.00, 101.09, 100.91, 100.88, 100.63, 100.58, 100.51, 99.20, 98.65, 81.13, 79.77, 78.77, 78.57, 77.66, 75.18, 73.21, 72.08, 71.96, 71.57, 71.04, 70.86, 70.76, 70.67, 70.62, 70.55, 70.18, 70.14, 70.06, 69.95, 69.15, 67.74, 67.50, 67.46, 67.42, 67.31, 67.25, 67.23, 66.76, 64.00, 63.65, 63.42, 63.35, 63.16, 63.03, 62.97, 21.63 -20 .58. after purification by chromatography on a Bio-Gel P2 column (2.7 cm x 100 cm). 23, 102.18, 100.72, 100.63, 100.53, 99.29, 99.18, 94.11, 78.75, 78.59, 78.57, 78.44, 78.35, 73.20, 73.18, 73.15, 73.11, 72.60, 70.73, 70.55, 70.47 ,   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   17 70. 23, 70.21, 70.03, 69.93, 69.86, 69.41, 66.86, 66.83, 66.70, 66.64, 66.60, 65.68, 65.60, 65.17, 60.98, 60.84 The product was obtained as a white solid (74 mg, 0.05 mmol, 90%) after purification by chromatography on a Bio-Gel P2 column (2.7 x 100 cm). 16, 102.07, 102.04, 100.60, 100.56, 100.47, 99.34, 97.82, 94.04, 93.55, 78.75, 78.56, 78.51, 78.47, 78.42, 78.33, 73.12, 73.10, 73.08, 73.02, 73.00, 72.53, 70.94, 70.47, 70.14, 70.08, 69.93, 69.86, 69.79, 69.35, 66.80, 66.74, 66.71, 66.64, 66.62, 65.50, 65.46, 65.42, 65.26, 65.24, 65.17, 60.98, 60.93, 60.86, 60.78, 60.76 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   18 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 19
